A Swiss drugmaker is challenging a 2011 change to the law that no longer allows a company to patent an invention if it was for sale for more than a year before filing a patent application. Meanwhile, Congress also plans to focus on the issue of pharmaceutical patents and lawmakers continue to question the industry's pricing decisions. And as Capitol Hill gears up for potential action on drug costs, there may be some lessons to be learned from China.

from Kaiser Health News https://ift.tt/2G6Oa5v

Related Posts:

0 comments:

Post a Comment

Popular Posts